| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 48 Number 5
Volume 48 Number 4
Volume 48 Number 3
Volume 48 Number 2
Volume 48S Number 1
Volume 48 Number 1
Earlier issues
Volume 48 Number 3

Research articles

ScienceAsia 48 (2022): 776-781 |doi: 10.2306/scienceasia1513-1874.2022.113

Development of lipoyl-substituted porphyrins as novel biocompatible mitochondria-targeting agents

Apiratt Thitimona, Vitavat Aksornkittib, Amornpun Sereemaspunb, Patchanita Thamyongkita, Vinich Promarakc, Rojrit Rojanathanesa,*

ABSTRACT:     This work describeed synthesis and investigation of a novel water-soluble lipoyl-substituted porphyrin derivative and its Mn(III)-complex for mitochondria-targeting activities. The freebase derivative was obtained in moderate yield from alkylation of 5,10,15,20-tetra(4-pyridyl)porphyrin followed by amidation with lipoic acid anhydride. Mn-metallation of the freebase derivative quantitatively produced the target Mn(III)-porphyrin. Both lipoyl-substituted porphyrin and Mn(III)-complex were fully characterized by NMR spectroscopy, mass spectrometry, absorption spectrophotometry, and emission spectrophotometry. Both compounds were considered to have low cytotoxicity with IC50 values of 29?49 and more than 78 ?M, respectively, against the HaCaT and HDFa cells. In addition, mitochondria- targeting evaluation suggested that these target porphyrin derivatives exhibited accumulation, specifically in the mitochondria of the HaCaT cells.

Download PDF

6 Downloads 52 Views

a Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330 Thailand
b Nanomedicine Research Unit, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330 Thailand
c School of Molecular Science and Engineering, Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong 21210 Thailand

* Corresponding author, E-mail: rojrit@hotmail.com

Received 13 Mar 2022, Accepted 1 Jun 2022